Floatz logo

236 assets in Ovarian Carcinoma

Therapeutic assets addressing Ovarian Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Alpelisib
Ovarian Carcinoma
National Cancer Institute (NCI)P2B (59)
Dpx-Survivac
Ovarian Carcinoma
ImmunoVaccine Technologies, Inc. (IMV Inc.)P2B (59)
Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter
Ovarian Carcinoma
Mayo ClinicP2B (59)
Vismodegib
Ovarian Carcinoma
OHSU Knight Cancer InstituteP2B (59)
Adavosertib
Ovarian Carcinoma
M.D. Anderson Cancer CenterP2B (58)
Capivasertib
Ovarian Carcinoma
National Cancer Institute (NCI)P2B (58)
Cbx-12
Ovarian Carcinoma
Cybrexa TherapeuticsP2B (58)
Pamiparib
Ovarian Carcinoma
Sun Yat-sen UniversityP2B (58)
Sapanisertib
Ovarian Carcinoma
National Cancer Institute (NCI)P2B (58)
Etoposide
Ovarian Carcinoma
Fudan UniversityP2B (57)
Fludarabine
Ovarian Carcinoma
Beijing BiotechP2B (57)
Immunoglobulin G1 [300-Alanine], Anti-(Human Cd73 Antigen) (Human-Mus Musculus Monoclonal Tj004309 ?1-Chain), Disulfide With Human-Mus Musculus Monoclonal Tj004309 ?-Chain, Dimer
Ovarian Carcinoma
I-Mab Biopharma US LimitedP2B (57)
mk-4830
Ovarian Carcinoma
Merck Sharp & Dohme LLCP2B (57)
Dasatinib
Ovarian Carcinoma
National Cancer Institute (NCI)P2B (56)
Pegfilgrastim
Ovarian Carcinoma
TORL Biotherapeutics, LLCP2/3B (56)
Defactinib
Ovarian Carcinoma
Verastem, Inc.P2CCC (55)
Immunoglobulin G1-Kappa, Anti-[Homo Sapiens Cldn6 (Claudin 6, Claudin-6)], Monoclonal Antibody (Ixotatug)
Ovarian Carcinoma
TORL Biotherapeutics, LLCP2CCC (55)
Sacituzumab Tirumotecan
Ovarian Carcinoma
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.P2CCC (55)
Tuvonralimab
Ovarian Carcinoma
Fudan UniversityP2CCC (55)
azd5335
Ovarian Carcinoma
AstraZenecaP3CCC (54)
Bl-M07D1
Ovarian Carcinoma
Sichuan Baili Pharmaceutical Co., Ltd.P3CCC (54)
Fluzoparib
Ovarian Carcinoma
Anhui Provincial HospitalP3CCC (54)
Immunoglobulin G1 [De-448-Lysine], Anti-(Human Epidermal Growth Factor Receptor) (Human-Mouse Monoclonal C225 ?1-Chain) Fusion Protein With Peptide Linker (Ggggs)2 Fusion Protein With Immunoglobulin Anti-(Human Epidermal Growth Factor Receptor Her3) (Human Clone Her3.H3 Single-Chain Variable Fragment Vh-(Ggggs)3-Vl), Complex With Human-Mouse Monoclonal C225 ?-Chain, Dimer, 214??,214???,222,222?,228,228?,231,231?-Octakis(Thioether) With (2S)-N-(Carboxymethyl)-2-(3-Mercapto-2,5-Dioxo-1-Pyrrolidinyl)-?-Alanylglycylglycyl-L-Phenylalanyl-N-[[(1S)-2-[[(1S,9S)-9-Ethyl-5-Fluoro-2,3,9,10,13,15-Hexahydro-9-Hydroxy-4-Methyl-10,13-Dioxo-1H,12H-Benzo[De]Pyrano[3?,4?:6,7]Indolizino[1,2-B]Quinolin-1-Yl]Amino]-1-Methyl-2-Oxoethoxy]Methyl]Glycinamide
Ovarian Carcinoma
Sichuan Baili Pharmaceutical Co., Ltd.P3CCC (54)
Oregovamab
Ovarian Carcinoma
CanariaBio Inc.P3CCC (54)
Panitumumab
Ovarian Carcinoma
National Cancer Institute (NCI)P2CCC (54)
Peg-Pei-Cholesterol Lipopolymer
Ovarian Carcinoma
ImunonP3CCC (54)
Pumvc3-Higfbp-2 Multi-Epitope Plasmid Dna Vaccine
Ovarian Carcinoma
University of WashingtonP2CCC (54)
rc88
Ovarian Carcinoma
RemeGen Co., Ltd.P2CCC (54)
Rivoceranib
Ovarian Carcinoma
Anhui Provincial HospitalP3CCC (54)
Adsorbed Purified Pertussis Vaccine
Ovarian Carcinoma
Mayo ClinicP2CCC (53)
Anetumab Ravtansine
Ovarian Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Atovaquone
Ovarian Carcinoma
Emory UniversityP2CCC (53)
Atropine
Ovarian Carcinoma
National Cancer Institute (NCI)P2CCC (53)
b1962
Ovarian Carcinoma
Tasly Biopharmaceuticals Co., Ltd.P2CCC (53)
Belzutifan
Ovarian Carcinoma
Dana-Farber Cancer InstituteP2CCC (53)
Binimetinib
Ovarian Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Ceralasertib
Ovarian Carcinoma
M.D. Anderson Cancer CenterP2CCC (53)
Cilostazol
Ovarian Carcinoma
Emory UniversityP2CCC (53)
Copanlisib
Ovarian Carcinoma
M.D. Anderson Cancer CenterP2CCC (53)
Crizotinib
Ovarian Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Dabrafenib
Ovarian Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Diphtheria Toxoid
Ovarian Carcinoma
Mayo ClinicP2CCC (53)
Diphtheria Toxoid Adsorbed
Ovarian Carcinoma
Mayo ClinicP2CCC (53)
Disitamab
Ovarian Carcinoma
Peking University Cancer Hospital & InstituteP2CCC (53)
Epirubicin
Ovarian Carcinoma
Groupe Hospitalier Diaconesses Croix Saint-SimonP2CCC (53)
Exemestane
Ovarian Carcinoma
OHSU Knight Cancer InstituteP2CCC (53)
Fexagratinib
Ovarian Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Gsk-2636771
Ovarian Carcinoma
National Cancer Institute (NCI)P2CCC (53)
her3-dxd
Ovarian Carcinoma
Daiichi SankyoP2CCC (53)
Ipatasertib
Ovarian Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Showing 51 to 100 of 236 assets
PreviousPage 2 of 5Next